Get the Stockscreener App
6.35
0.63%
0.04
After Hours:
6.47
0.12
+1.89%
Astria Therapeutics Inc stock is traded at $6.35, with a volume of 242.45K.
It is up +0.63% in the last 24 hours and up +1.44% over the past month.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
See More
Previous Close:
$6.31
Open:
$6.22
24h Volume:
242.45K
Relative Volume:
0.69
Market Cap:
$358.36M
Revenue:
-
Net Income/Loss:
$-72.89M
P/E Ratio:
-2.624
EPS:
-2.42
Net Cash Flow:
$-68.47M
1W Performance:
-6.07%
1M Performance:
+1.44%
6M Performance:
-6.75%
1Y Performance:
-46.77%
1-Day Range:
$6.12
$6.45
1-Week Range:
$6.12
$7.14
52-Week Range:
$3.555
$12.92
Astria Therapeutics Inc Stock (ATXS) Company Profile
Name
Astria Therapeutics Inc
Sector
Industry
Phone
617-349-1971
Address
22 BOSTON WHARF ROAD, BOSTON
Compare ATXS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATXS
Astria Therapeutics Inc
|
6.35 | 382.63M | 0 | -72.89M | -68.47M | -2.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.46 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
598.16 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
467.55 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
663.73 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.97 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-31-25 | Initiated | JMP Securities | Mkt Outperform |
| Jul-29-24 | Initiated | TD Cowen | Buy |
| Mar-28-23 | Initiated | Evercore ISI | Outperform |
Astria Therapeutics Inc Stock (ATXS) Latest News
Astria Therapeutics Inc. stock volume spike explained2025 Buyback Activity & Entry Point Confirmation Alerts - Newser
Signal strength of Astria Therapeutics Inc. stock in tech scannersEarnings Miss & Consistent Growth Stock Picks - Newser
Is Astria Therapeutics Inc. stock ready for a breakoutTrade Risk Assessment & Capital Efficiency Focused Ideas - Newser
Forecasting Astria Therapeutics Inc. price range with options data2025 Trading Volume Trends & Long-Term Growth Stock Strategies - Newser
Published on: 2025-08-19 23:26:47 - Newser
Will Astria Therapeutics Inc. continue its uptrendQuarterly Risk Review & Weekly Top Gainers Alerts - Newser
Why Astria Therapeutics Inc. stock attracts strong analyst attentionQuarterly Performance Summary & Weekly Watchlist for Consistent Profits - Newser
Can trapped investors hope for a rebound in Astria Therapeutics Inc.Entry Point & Technical Pattern Alert System - Newser
Can Astria Therapeutics Inc. hit a new high this month2025 Momentum Check & Risk Adjusted Swing Trade Ideas - Newser
Will Astria Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsShare Buyback & Capital Protection Trading Alerts - Newser
Technical signs of recovery in Astria Therapeutics Inc.Quarterly Portfolio Report & Stepwise Trade Signal Implementation - Newser
Long term hold vs stop loss in Astria Therapeutics Inc.2025 Macro Impact & Free Safe Entry Trade Signal Reports - Newser
Healthcare Sector Analysts Offer Insights on Revolution Medicines, Astria Therapeutics, and AbbVie - AInvest
Is This the Dip to Buy in Astria Therapeutics Inc.Market Risk Analysis & Stepwise Trade Execution Plans - newsimpact.co.kr
Astria Therapeutics Reports Q2 2025 Earnings Loss, Market Reacts with Mixed Short-Term Volatility - AInvest
Is Astria Therapeutics Inc. showing signs of accumulationJuly 2025 Price Swings & Verified Entry Point Signals - Newser
Astria Therapeutics Inc. stock momentum explainedQuarterly Risk Review & High Win Rate Trade Alerts - Newser
Astria Therapeutics Q2 Earnings Miss: Mixed Short-Term Market Impact and Recovery Signals - AInvest
Applying sector rotation models to Astria Therapeutics Inc.2025 Investor Takeaways & Expert Approved Trade Ideas - Newser
what makes astria therapeutics inc. stock price move sharplyFree Sector Rotation Based Trading Opportunities - Newser
FY2025 EPS Estimates for ATXS Increased by Cantor Fitzgerald - Defense World
Financial Analysis: Arcellx (NASDAQ:ACLX) and Astria Therapeutics (NASDAQ:ATXS) - Defense World
How high can Astria Therapeutics Inc. stock goMarket Activity Summary & Free High Return Stock Watch Alerts - Newser
Price action breakdown for Astria Therapeutics Inc.July 2025 Snapshot & Advanced Swing Trade Entry Plans - Newser
What earnings revisions data tells us about Astria Therapeutics Inc.July 2025 PostEarnings & Real-Time Volume Trigger Notifications - Newser
Published on: 2025-08-16 17:45:58 - metal.it
Is Astria Therapeutics Inc. a candidate for recovery playJuly 2025 Big Picture & Smart Investment Allocation Tips - Newser
Does Astria Therapeutics (ATXS) Have the Potential to Rally 333.88% as Wall Street Analysts Expect? - msn.com
Q3 EPS Forecast for Astria Therapeutics Raised by Analyst - Defense World
Q3 Earnings Forecast for ATXS Issued By Lifesci Capital - Defense World
Equities Analysts Set Expectations for ATXS Q3 Earnings - Defense World
JMP Securities Increases Astria Therapeutics (NASDAQ:ATXS) Price Target to $26.00 - Defense World
Astria Therapeutics Reports Increased Losses Amid R&D Expansion - TipRanks
Astria Therapeutics Inc Stock (ATXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.55%
0.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):